Clinical Trial Update: An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]

View source ↗

Summary

Phase 3 trial update of BG00012 (Dimethyl Fumarate) in Asian subjects with relapsing-remitting multiple sclerosis (RRMS) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BG00012 (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | Phase 3 | Status: COMPLETED